Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 67.81
NXTM's Cash to Debt is ranked higher than
81% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. NXTM: 67.81 )
NXTM' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 67.81

Equity to Asset 0.62
NXTM's Equity to Asset is ranked higher than
71% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NXTM: 0.62 )
NXTM' s 10-Year Equity to Asset Range
Min: -4.58   Max: 0.89
Current: 0.62

-4.58
0.89
F-Score: 3
Z-Score: 3.45
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -6.76
NXTM's Operating margin (%) is ranked higher than
62% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. NXTM: -6.76 )
NXTM' s 10-Year Operating margin (%) Range
Min: -37110   Max: -4.63
Current: -6.76

-37110
-4.63
Net-margin (%) -7.05
NXTM's Net-margin (%) is ranked higher than
62% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. NXTM: -7.05 )
NXTM' s 10-Year Net-margin (%) Range
Min: -36600   Max: -6.26
Current: -7.05

-36600
-6.26
ROE (%) -9.56
NXTM's ROE (%) is ranked higher than
62% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. NXTM: -9.56 )
NXTM' s 10-Year ROE (%) Range
Min: -48.6   Max: -7.67
Current: -9.56

-48.6
-7.67
ROA (%) -6.05
NXTM's ROA (%) is ranked higher than
62% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. NXTM: -6.05 )
NXTM' s 10-Year ROA (%) Range
Min: -137.54   Max: -4.86
Current: -6.05

-137.54
-4.86
ROC (Joel Greenblatt) (%) -19.78
NXTM's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. NXTM: -19.78 )
NXTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -346.31   Max: -18.01
Current: -19.78

-346.31
-18.01
Revenue Growth (%) 5.50
NXTM's Revenue Growth (%) is ranked higher than
74% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. NXTM: 5.50 )
NXTM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 373.3
Current: 5.5

0
373.3
EPS Growth (%) -22.30
NXTM's EPS Growth (%) is ranked higher than
55% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. NXTM: -22.30 )
NXTM' s 10-Year EPS Growth (%) Range
Min: -34.6   Max: 1.1
Current: -22.3

-34.6
1.1
» NXTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NXTM Guru Trades in Q2 2013

Steven Cohen 488,307 sh (New)
Jim Simons 132,300 sh (-61.3%)
» More
Q3 2013

NXTM Guru Trades in Q3 2013

Steven Cohen 659,082 sh (+34.97%)
Jim Simons 69,600 sh (-47.39%)
» More
Q4 2013

NXTM Guru Trades in Q4 2013

Paul Tudor Jones 20,600 sh (New)
Steven Cohen 1,148,700 sh (+74.29%)
Jim Simons Sold Out
» More
Q1 2014

NXTM Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen 1,081,000 sh (-5.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.09%$10.61 - $13.73 $ 13.1513%0
John Burbank 2012-09-30 New Buy0.09%$12.47 - $17.04 $ 13.15-8%150000
Ron Baron 2012-06-30 Sold Out 0.02%$14.94 - $19.44 $ 13.15-20%0
Ron Baron 2012-03-31 New Buy0.02%$16.55 - $21.54 $ 13.15-26%176418
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about NxStage Medical Inc

Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP
According to GuruFocus list of 3-year lows: Multi-Fineline Electronix Inc, NxStage Medical Inc, CVR Refining LP, and Crestwood Midstream Partners LP have all reached their 3-year lows. Read more...

Ratios

vs
industry
vs
history
P/B 4.19
NXTM's P/B is ranked higher than
63% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. NXTM: 4.19 )
NXTM' s 10-Year P/B Range
Min: 0.8   Max: 14.22
Current: 4.19

0.8
14.22
P/S 2.92
NXTM's P/S is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. NXTM: 2.92 )
NXTM' s 10-Year P/S Range
Min: 0.66   Max: 16.71
Current: 2.92

0.66
16.71
EV-to-EBIT -40.57
NXTM's EV-to-EBIT is ranked higher than
61% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. NXTM: -40.57 )
NXTM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -40.57

Current Ratio 3.28
NXTM's Current Ratio is ranked higher than
80% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. NXTM: 3.28 )
NXTM' s 10-Year Current Ratio Range
Min: 1.71   Max: 10.48
Current: 3.28

1.71
10.48
Quick Ratio 2.37
NXTM's Quick Ratio is ranked higher than
78% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. NXTM: 2.37 )
NXTM' s 10-Year Quick Ratio Range
Min: 0.75   Max: 9.59
Current: 2.37

0.75
9.59

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.01
NXTM's Price/Tangible Book is ranked higher than
69% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. NXTM: 6.01 )
NXTM' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 106.11
Current: 6.01

2.39
106.11
Price/Median PS Value 0.77
NXTM's Price/Median PS Value is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. NXTM: 0.77 )
NXTM' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 3.71
Current: 0.77

0.23
3.71
Forward Rate of Return (Yacktman) -1.39
NXTM's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. NXTM: -1.39 )
NXTM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.2   Max: 45
Current: -1.39

-10.2
45

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:N5X.Germany
NxStage Medical, Inc was incorporated in Delaware in 1998 under the name QB Medical, Inc., and later changed its name to NxStage Medical, Inc. NxStage is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its main product, the NxStage System One was designed to satisfy an unmet clinical need for a system that could deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that could be used by healthcare professionals and trained lay users alike in a number of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent, or 'daily,' dialysis. The System One is cleared by the United States Food and Drug Administration for home hemodialysis as well as hospital and clinic-based dialysis. It also sells needles and blood tubing sets mainly to dialysis clinics for the treatment of End Stage Renal Disease, or ESRD. The Company has two reporting segments, System One and In-Center. It distributes its products in three markets: the home, critical care and in-center. Within the System One segment, the Company sells and rentals System One and PureFlow SL equipment and sells disposable products in the home and critical care markets. The home market consists of dialysis centers that provide treatment options for patients that have ESRD, while the critical care market consists of hospitals or facilities that treat patients that have suddenly, and possibly temporarily, lost kidney function. The company sells essentially the same System One cyclers and disposables within each market and some of the company's largest customers in the home market provide outsourced renal dialysis services to hospitals in the critical care market to which the company sells System One cyclers and disposables. Sales of products to both markets are made through dedicated sales forces and products are distributed directly to the customer. Within the In-Center segment, the Company sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors. The Company competes with Fresenius, Gambro, Nipro, Baxter International, Inc., or Baxter, JMS and others. The Company is subject to government regulation in the countries in which it conducts business. In the foreign countries in which the Company market and sell its products, it is subject to local regulations affecting, among other things, design and product standards, packaging and labeling and promotion requirements.
» More Articles for NXTM

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
NxStage® to Report Second Quarter 2014 Financial Results Jul 17 2014
NxStage® to Report Second Quarter 2014 Financial Results Jul 17 2014
NxStage Drives to Educate Kidney Patients Jul 16 2014
NxStage Drives to Educate Kidney Patients Jul 16 2014
NxStage Kidney Care Hosts Grand Opening Celebration Of New State-Of-The-Art Dialysis Center In... Jul 08 2014
NxStage Kidney Care Hosts Grand Opening Celebration Of New State-Of-The-Art Dialysis Center In... Jul 08 2014
NxStage Joins Patients in Celebrating Independence Jul 03 2014
NxStage Joins Patients in Celebrating Independence Jul 03 2014
NxStage Medical reiterated Outperform after CMS rule at William Blair Jul 03 2014
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Jun 16 2014
Avid Motorcyclist and NxStage Patient Reclaims His Life Jun 12 2014
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 28 2014
Flexibility of Home Hemodialysis with NxStage System One Allows Patient to Achieve Life Milestone May 19 2014
NXSTAGE MEDICAL, INC. Financials May 16 2014
NxStage to Present at the William Blair Growth Stock Conference May 15 2014
NxStage Medical's (NXTM) CEO Jeff Burbank on Q1 2014 Results - Earnings Call Transcript May 08 2014
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
NxStage Medical sees Q2 revenue $70M-$71.5M, consensus $70.46M May 08 2014
NxStage Medical sees FY14 revenue to be in higher end of $283M-$288M May 08 2014
NxStage Medical reports Q1 EPS (9c), consensus (11c) May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide